The Experts below are selected from a list of 405 Experts worldwide ranked by ideXlab platform
Michel Dib - One of the best experts on this subject based on the ideXlab platform.
-
double blind comparative study of cyamemazine vs bromazepam in the Benzodiazepine Withdrawal Syndrome
Progress in Neuro-psychopharmacology & Biological Psychiatry, 2006Co-Authors: Patrick Lemoine, Imane Kermadi, Stephanie Garciaacosta, Ricardo P Garay, Michel DibAbstract:Cyamemazine is an anxiolytic antipsychotic, which reduces ethanol Withdrawal symptoms. Here, we investigated if cyamemazine can be also effective as substitute drug to facilitate Benzodiazepine Withdrawal. A total of 168 patients treated with Benzodiazepines for at least 3 months and with a <18 score in the Hamilton Anxiety Rating Scale (HARS) were included in the study. Previous Benzodiazepine treatment was withdrawn, and patients were randomized to a 4-week treatment with cyamemazine (25-50 mg q.d.) or bromazepam (3-6 mg q.d.), followed by 2 weeks of placebo. The primary efficacy variable was the maximal anxiety rebound as measured with the HARS during the 42 days of treatment. No statistically significant differences between treatment groups were found for the extent or incidence of rebound anxiety. Considering all dropout patients as Withdrawal failures, after 6 months of follow-up, 56/84 patients in the cyamemazine group (66.7%) and 55/84 patients in the bromazepam group (65.5%) were successfully withdrawn. 28 patients in the cyamemazine group and 18 in the bromazepam group had an adverse event, including anxiety, insomnia, dry mouth and somnolence. No extra-pyramidal symptoms were reported. In conclusion, cyamemazine was comparable to bromazepam in ensuring successful Benzodiazepine Withdrawal and in controlling the acute Benzodiazepine Withdrawal Syndrome. Cyamemazine may be useful to facilitate Benzodiazepine Withdrawal in those patients where bromazepam substitution is not appropriate.
M Garreau - One of the best experts on this subject based on the ideXlab platform.
-
a randomized double blind study of alpidem vs placebo in the prevention and treatment of Benzodiazepine Withdrawal Syndrome
European Psychiatry, 1996Co-Authors: G B Cassano, A Petracca, C Borghi, S Chiroli, G Didoni, M GarreauAbstract:The aim of the trial was to assess alpidem efficacy in preventing and treating the Benzodiazepine (BZ) Withdrawal Syndrome (WS). A multicentre, double-blind, randomized versus placebo, parallel group study of six-week duration was carried out in outpatients suffering from generalized anxiety or adjustment disorder with an anxious mood and taking non-hypnotic BZ as continuous course of therapy of at least one-year duration. At the entry, the patients abruptly discontinued BZs and were treated with 50 mg/bid/tid of alpidem or placebo. Withdrawal Syndrome diagnosis was (regarding treatment allocation) formulated by an independent psychiatrist, according to DSM-III-R and an appropriate scale, the SESSB. One hundred seventy-three patients were randomized and 148 completed the study. Withdrawal Syndrome occurred in 27 patients of the alpidem group (31.0%) and in 38 patients of the placebo group (44.2%). A severe WS was diagnosed in 11.1% of the patients in the alpidem group and in 31.6% of the placebo group. If not having been withdrawn from the market, alpidem could have been useful for the prevention of BZ Withdrawal Syndrome.
Patrick Lemoine - One of the best experts on this subject based on the ideXlab platform.
-
double blind comparative study of cyamemazine vs bromazepam in the Benzodiazepine Withdrawal Syndrome
Progress in Neuro-psychopharmacology & Biological Psychiatry, 2006Co-Authors: Patrick Lemoine, Imane Kermadi, Stephanie Garciaacosta, Ricardo P Garay, Michel DibAbstract:Cyamemazine is an anxiolytic antipsychotic, which reduces ethanol Withdrawal symptoms. Here, we investigated if cyamemazine can be also effective as substitute drug to facilitate Benzodiazepine Withdrawal. A total of 168 patients treated with Benzodiazepines for at least 3 months and with a <18 score in the Hamilton Anxiety Rating Scale (HARS) were included in the study. Previous Benzodiazepine treatment was withdrawn, and patients were randomized to a 4-week treatment with cyamemazine (25-50 mg q.d.) or bromazepam (3-6 mg q.d.), followed by 2 weeks of placebo. The primary efficacy variable was the maximal anxiety rebound as measured with the HARS during the 42 days of treatment. No statistically significant differences between treatment groups were found for the extent or incidence of rebound anxiety. Considering all dropout patients as Withdrawal failures, after 6 months of follow-up, 56/84 patients in the cyamemazine group (66.7%) and 55/84 patients in the bromazepam group (65.5%) were successfully withdrawn. 28 patients in the cyamemazine group and 18 in the bromazepam group had an adverse event, including anxiety, insomnia, dry mouth and somnolence. No extra-pyramidal symptoms were reported. In conclusion, cyamemazine was comparable to bromazepam in ensuring successful Benzodiazepine Withdrawal and in controlling the acute Benzodiazepine Withdrawal Syndrome. Cyamemazine may be useful to facilitate Benzodiazepine Withdrawal in those patients where bromazepam substitution is not appropriate.
G B Cassano - One of the best experts on this subject based on the ideXlab platform.
-
a randomized double blind study of alpidem vs placebo in the prevention and treatment of Benzodiazepine Withdrawal Syndrome
European Psychiatry, 1996Co-Authors: G B Cassano, A Petracca, C Borghi, S Chiroli, G Didoni, M GarreauAbstract:The aim of the trial was to assess alpidem efficacy in preventing and treating the Benzodiazepine (BZ) Withdrawal Syndrome (WS). A multicentre, double-blind, randomized versus placebo, parallel group study of six-week duration was carried out in outpatients suffering from generalized anxiety or adjustment disorder with an anxious mood and taking non-hypnotic BZ as continuous course of therapy of at least one-year duration. At the entry, the patients abruptly discontinued BZs and were treated with 50 mg/bid/tid of alpidem or placebo. Withdrawal Syndrome diagnosis was (regarding treatment allocation) formulated by an independent psychiatrist, according to DSM-III-R and an appropriate scale, the SESSB. One hundred seventy-three patients were randomized and 148 completed the study. Withdrawal Syndrome occurred in 27 patients of the alpidem group (31.0%) and in 38 patients of the placebo group (44.2%). A severe WS was diagnosed in 11.1% of the patients in the alpidem group and in 31.6% of the placebo group. If not having been withdrawn from the market, alpidem could have been useful for the prevention of BZ Withdrawal Syndrome.
Stephanie Garciaacosta - One of the best experts on this subject based on the ideXlab platform.
-
double blind comparative study of cyamemazine vs bromazepam in the Benzodiazepine Withdrawal Syndrome
Progress in Neuro-psychopharmacology & Biological Psychiatry, 2006Co-Authors: Patrick Lemoine, Imane Kermadi, Stephanie Garciaacosta, Ricardo P Garay, Michel DibAbstract:Cyamemazine is an anxiolytic antipsychotic, which reduces ethanol Withdrawal symptoms. Here, we investigated if cyamemazine can be also effective as substitute drug to facilitate Benzodiazepine Withdrawal. A total of 168 patients treated with Benzodiazepines for at least 3 months and with a <18 score in the Hamilton Anxiety Rating Scale (HARS) were included in the study. Previous Benzodiazepine treatment was withdrawn, and patients were randomized to a 4-week treatment with cyamemazine (25-50 mg q.d.) or bromazepam (3-6 mg q.d.), followed by 2 weeks of placebo. The primary efficacy variable was the maximal anxiety rebound as measured with the HARS during the 42 days of treatment. No statistically significant differences between treatment groups were found for the extent or incidence of rebound anxiety. Considering all dropout patients as Withdrawal failures, after 6 months of follow-up, 56/84 patients in the cyamemazine group (66.7%) and 55/84 patients in the bromazepam group (65.5%) were successfully withdrawn. 28 patients in the cyamemazine group and 18 in the bromazepam group had an adverse event, including anxiety, insomnia, dry mouth and somnolence. No extra-pyramidal symptoms were reported. In conclusion, cyamemazine was comparable to bromazepam in ensuring successful Benzodiazepine Withdrawal and in controlling the acute Benzodiazepine Withdrawal Syndrome. Cyamemazine may be useful to facilitate Benzodiazepine Withdrawal in those patients where bromazepam substitution is not appropriate.